COVID-19 Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0EV0H
|
|||
| Drug Name |
PMID26911565-peptide-P9
|
|||
| Synonyms |
PMID26911565-P9
|
|||
| Drug Type |
Protein/peptide drug
|
|||
| Indication | Middle East Respiratory Syndrome (MERS) | Preclinical | [1] | Severe acute respiratory syndrome (SARS) | Preclinical | [1] |
| Therapeutic Class |
Antiviral Agents
|
|||
| Target | Top | |||
|---|---|---|---|---|
| Target(s) | MERS-CoV spike glycoprotein (S) | Target Info | Inhibitor | [1] |
| A short peptide P9, exhibits potent and broad-spectrum antiviral effects against multiple respiratory viruses in vitro and in vivo, including SARS-CoV and MERS-CoV. The antiviral activity of P9 is attributed to its high-affinity binding to viral glycoproteins. | ||||
| SARS-CoV spike glycoprotein (S) | Target Info | Inhibitor | [1] | |
| A short peptide P9, exhibits potent and broad-spectrum antiviral effects against multiple respiratory viruses in vitro and in vivo, including SARS-CoV and MERS-CoV. The antiviral activity of P9 is attributed to its high-affinity binding to viral glycoproteins. | ||||
| References | Top | |||
|---|---|---|---|---|
| 1 | A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses. Sci Rep. 2016 Feb 25;6:22008. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.